financetom
Business
financetom
/
Business
/
J&J-backed Rapport Therapeutics shares debut nearly 6% higher
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
J&J-backed Rapport Therapeutics shares debut nearly 6% higher
Jun 7, 2024 8:46 AM

June 7 (Reuters) - Shares of Rapport Therapeutics

, backed by Johnson & Johnson's ( JNJ ) venture capital

arm, rose nearly 6% in their market debut on Friday, valuing the

early stage therapy developer at $636.8 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved